Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Evergy Inc. Common Stock (EVRG) vs Gilead Sciences, Inc. (GILD) Price & Performance

Evergy Inc. Common StockTrade
Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

Evergy Inc. Common Stock vs Gilead Sciences, Inc. — how do they compare? Evergy Inc. Common Stock trades at $80.89 (market cap $18.57B), while Gilead Sciences, Inc. trades at $151.24 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 9.8× Evergy Inc. Common Stock's market cap, and Evergy Inc. Common Stock pays the higher dividend (3.45%). Which is the better fit depends on your goals — on Pluang, investors hold Evergy Inc. Common Stock for 1 Days and Gilead Sciences, Inc. for 111 Days on average.

EVRGGILD
Market Cap
$18.57B$182.40B
Volume
1,988,6754,469,821
Sector
UtilitiesHealth
52-Week High
$88.13$155.80
52-Week Low
$72.31$116.74
Typical Hold Time
1 Days111 Days
Enterprise Value
$35.04B$205.46B
Dividend Yield
3.45%2.23%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Evergy Inc. Common Stock

No Aura AI signal available yet.

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.

Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EVRG

No sentiment data available yet.

GILD
26% Buy74% Sell
Avg holding period · 111 Days

About Evergy Inc. Common Stock

Evergy is a regulated electric utility serving customers in Kansas and Missouri. Its operations include electricity generation, transmission, and distribution through its integrated utility subsidiaries.

Read more on EVRG →

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD →